A new TRAIL to therapy of hepatocellular carcinoma: Blocking the proteasome

Hepatology

Volumn 42, Issue 3, 2005, Pages 527-529

  Anan, Akira ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 10; CASPASE 8; CCAAT ENHANCER BINDING PROTEIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; PROTEASOME; PROTEASOME INHIBITOR; TRAIL AGONIST; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

CELL TRANSFORMATION; CYTOTOXICITY; EDITORIAL; HUMAN; LIGAND BINDING; LIVER CELL CARCINOMA; LIVER TOXICITY; MOLECULAR MECHANICS; NEUROPATHY; PRIORITY JOURNAL;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MEMBRANE GLYCOPROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 24144431555     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20869     Document Type: Editorial

References (28)

1. Carr BI. Hepatocellular carcinoma; current management and future trends. Gastroenterology 2004(5 Suppl 1);127:S218-S224.
2. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622.
3. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-14379.
4. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-639.
5. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000;14;65-77.
6. Masdehors P, Omura S, Merle-Beral H, Mentz F, Cosset JM, Dumont J, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-speciftc inhibitor lactacystin. Br J Haematol 1999;105:752-757.
7. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, Takekoshi T, et al. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000;6:916-923.
8. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-360.
9. Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, et al. Proteasome: an emerging target for cancer therapy. Anticancer Drugs 2005;16:475-481.
10. Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, et al. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res 2005;11:3410-3416.
11. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-162.
12. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163.
13. Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy. J Clin Oncol 2003;21: 3526-3534.
14. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611-620.
15. Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. HEPATOLOGY 2000;32:482-490.
16. Kim YS, Schwabe RF, Qian T, Lemasters JJ, Brenner DA. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. HEPATOLOGY 2002;36; 1498-1508.
17. Gores GJ, Kaufmann SH. Is TRAIL hepatotoxic? HEPATOLOGY 2001;34: 3-6.
18. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61:3535-3540.
19. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004;23:2009-2015.
20. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005;4:443-449.
21. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. HEPATOLOGY 2005;42:588-597.
22. Shankar S, Srivastava RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat 2004;7:139-156.
23. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003;22: 4953-4963.
24. He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 2004;23:2554-2558.
25. Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, et al. Proteasome Inhibitor MG132 Induces Death Receptor 5 through CCAAT/Enhancer-Binding Protein Homologous Protein. Cancer Res 2005;65:5662-5667.
26. Boatright KM, Deis C, Denault JB, Sutherlin DP, Salvesen GS. Activation ofcaspases-8 and -10 by FLIP(L). Biochem J 2004;382:651-657.
27. Sharp DA, Lawrence DA, Ashkenazi A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 2005;280: 19401-19409.
28. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-4427.